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timekeeping mechanism. Such circadian rhythms, and their underlying molecular
mechanisms, are known to be altered by a number of central nervous system acting
pharmacological compounds, as well as becoming perturbed in a number of common
psychiatric and neurological conditions. The psychostimulant methylphenidate and the
non-stimulant atomoxetine are used in the pharmacotherapy of attention deficit hyper-
activity disorder, a common condition in which circadian rhythms have been reported to
be altered. In the present study we have examined the effects of daily methylphenidate or
atomoxetine treatment across 7 days on circadian clock gene product expression across
numerous brain regions in the male mouse to test the potential impact of such compounds
on circadian timing. We report drug, brain region and molecular specific effects of such
treatments, including alterations in expression profiles in the suprachiasmatic nucleus,
the master circadian pacemaker. These results indicate that drugs used in the clinical
management of attention deficit hyperactivity disorder can alter molecular factors that are
believed to underpin circadian timekeeping, and such effects may be of importance in both
the therapeutic and side effect profiles of such drugs.
& 2013 Elsevier B.V. All rights reserved.r B.V. All rights reserved.
8
ccumbens; AcbSh, shell of the nucleus accumbens; ADHD, attention deficit hyperactivity
ral amygdala; CC, cingulate cortex; CEA, central nucleus of the amygdala; CPu, caudate
dentate gyrus; DMH, dorsomedial nucleus of the hypothalamus; ILC, infralimbic cortex;
ne transporter; PER, PERIOD; PLC, prelimbic cortex; PVN, paraventricular nucleus of the
iasmatic nucleus; ZT, zeitgeber time
A.N. Coogan).
e study.
Kings College London, UK.
b r a i n r e s e a r c h 1 5 1 3 ( 2 0 1 3 ) 6 1 – 7 1621. Introduction
Attention deficit-hyperactivity disorder (ADHD) is a common
psychiatric condition of both childhood and adulthood, char-
acterised by the core symptoms of impulsivity, inattention
and hyperactivity (Coogan et al., 2012). The psychostimulant
methylphenidate (MPD) and the non-stimulant atomoxetine
(ATO) are used for the management of attention deficit
hyperactivity disorder (ADHD) in both children and adults
(Biederman and Faraone, 2005). Both drugs exert their ther-
apeutic action through manipulation of the catecholaminer-
gic systems, with MPD increasing the synaptic concentration
of both dopamine and noradrenaline, though inhibition of
the dopamine transporter (DAT) and the norepinephrine
transporter (NET), whilst ATO is an inhibitor of the NET and
increases synaptic noradrenaline levels (Madras et al., 2005).
Sleep deficits are commonly observed in ADHD (Sobanski
et al., 2008), and both beneficial and adverse effects of MPD
and ATO on various aspects of sleep have been documented
in ADHD (Boonstra et al., 2007). Circadian disturbances in
adult ADHD at the behavioural, molecular and endocrine
levels have also been shown (Baird et al., 2011) as well as
genetic associations between ADHD and clock gene poly-
morphisms (Kissling et al., 2008). The circadian clock is
responsible for the generation of circadian rhythms, which
are recurring patterns of behaviour and physiology on a near
twenty-four period base and plays a key role in determining
the sleep/wake cycle (Dibner et al., 2010; Reppert and Weaver,
2002). The master circadian clock is located in the suprachias-
matic nuclei (SCN) of the anterior hypothalamus with otherFig. 1 – Modulation of clock gene products and c-Fos in the SCN by
illustrating the expression of PER1, PER2, CLOCK,and c-Fos in t
scale bar is 100 μm. B: Expression profiles of CLOCK, PER1, PER2
(MPD) and atomoxetine (ATO) groups. * represents Po0.05 for p
treatment group at that time-point compared to the value in th
represents the time of the daily injection.oscillators present throughout the brain and periphery
(Guilding and Piggins, 2007). The molecular basis of circadian
rhythm generation consists of positive and negative tran-
scriptional/translational feedback loops of “clock” genes and
their protein products (Dibner et al., 2010).
Numerous pharmacological agents are known to impact
upon the molecular circadian clock (e.g. Uz et al., 2005) and
the dopaminergic and noradrenergic systems are implicated
in circadian clock functioning (McClung et al., 2005;
Wongchitrat et al., 2009). MPD and ATO have both also been
shown to exert effects upon the mammalian circadian sys-
tem (chronic MPD treatment produces a circadian locomotor
rhythm in arrhythmic SCN-lesioned rats (Honma and Honma,
1992)) as well as on rodent diurnal rhythms (Algahim et al.,
2009,2010), whilst time-of day effects on behavioural sensiti-
zation to MPD have also been reported (Gaytan et al., 2000).
Recently it has been shown that ongoing MPD treatment of
mice via drinking water produces phase delays and length-
ened free running rhythms and also alters electrical dis-
charge rhythms of SCN neurons (Antle et al., 2012). Further,
acute ATO treatment has been shown to phase-shift the
rodent locomotor rhythm and to alter circadian clock gene
product expression (O’Keeffe et al., 2012).
Given the deficits of the circadian clock in ADHD and the
interactions of ADHD medication with sleep, it could be
postulated that the therapeutic properties and/or the adverse
side effects of these drugs in part could involve modulation of
the circadian clock. Our hypothesis for the current study was
that in the light of data concerning phase-shifting effects
of both MPD and ATO in rodents and the key role of themethylphenidate and atomoxetine. A: Photomicrographs
he SCN. The SCN is delineated by the dashed line and the
and c-Fos in the SCN in the saline (SAL), methylphenidate
airwise comparison between the value in the appropriate
e saline control group at the same time-point. The arrow
b r a i n r e s e a r c h 1 5 1 3 ( 2 0 1 3 ) 6 1 – 7 1 63circadian clock gene cycle in determining behavioural
rhythms, both ATO and MPD would produce altered diurnal
expression profiles of clock gene product expression in one orTable 1 – Summary of the acrophase (peaks of expression) of
examined in the study in the three treatment groups as indic
n.s. indicates that no significant 24 h fit for expression was d
Brain region Treatment Acrophase (h
CLOCK
SCN SAL n.s.
MPD n.s.
ATO n.s.
DMH SAL ZT8
MPD ZT2
ATO ZT2
PVN SAL ZT8
MPD ZT5
ATO ZT5
CA1 SAL n.s.
MPD n.s.
ATO n.s.
CA3 SAL n.s.
MPD n.s.
ATO n.s.
DG SAL n.s.
MPD n.s.
ATO n.s.
BLA SAL n.s.
MPD n.s.
ATO ZT2
CEA SAL n.s.
MPD n.s.
ATO n.s.
CC SAL n.s.
MPD n.s.
ATO ZT2
PLC SAL n.s.
MPD n.s.
ATO n.s.
ILC SAL n.s.
MPD n.s.
ATO n.s.
CPu SAL ZT20
MPD ZT2
ATO ZT5
AcbC SAL n.s.
MPD n.s.
ATO n.s.
AcbSh SAL n.s.
MPD n.s.
ATO n.s.
VTA SAL n.s.
MPD n.s.
ATO n.s.more brain areas implicated in circadian timing. As such, this
study represents the first analysis of the effects of MPD and
ATO on rhythmic clock gene product expression.clock gene products and c-Fos across the brain areas
ated by co-sinor analysis with a 24 h sinusoidal wave.
etected by co-sinor analysis.
)
PER1 PER2 c-Fos
ZT14 ZT14 ZT6
ZT14 ZT2 ZT6
ZT14 n.s. ZT6
ZT8 n.s. ZT14
ZT2 n.s. ZT2
ZT2 n.s. ZT2
ZT14 ZT14 ZT20
n.s. ZT14 ZT20
ZT2 ZT20 ZT8
ZT2 n.s. n.s.
n.s. n.s. ZT2
ZT2 ZT2 n.s.
ZT2 n.s. n.s.
n.s. n.s. n.s.
ZT2 n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. ZT2
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. ZT20 n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. ZT18
ZT2 ZT2 n.s.
ZT2 ZT14 n.s.
ZT2 ZT2 n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. n.s. n.s.
n.s. ZT20 n.s.
n.s. n.s. n.s.
n.s. ZT14 ZT20
n.s. n.s. ZT20
n.s. n.s. n.s.
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2.1. Diurnal clock protein expression in the hypothalamus
In the SCN, rhythmic PER1 expression was unaltered by either
MPD or ATO treatment (Fig. 1). There was a significant main
effect of treatment on PER2 expression (F2,70¼34.9, Po0.05)
and a significant interaction between time and treatment
(F6,70¼5.6, Po0.05) and post hoc testing showed that both MPD
and ATO treatment reduced SCN PER2 expression (Po0.001;
Fig. 1). SCN CLOCK expression was arrhythmic and unaltered
by methylphenidate or atomoxetine, nor was there any effect
of treatment on SCN c-Fos expression. Co-sinor analysis
reveals that for PER2 in the SCN the MPD treated animals
show an acrophase at ZT2 (compared to ZT14 in saline
animals) and ATO treated animals do not show rhythmic
PER2 expression (Table 1).
In the dorsomedial hypothalamus (DMH), there were no
main effects of treatment nor significant time x treatment
interactions for PER1, PER2 or CLOCK expression (Fig. 2A). c-
Fos expression was altered by treatment (F2,70¼6.2, Po0.05)
and there was also a time x treatment interaction (F6,70¼3.9,
Po0.05), with c-Fos levels in the MPD treated animals sig-
nificantly higher at ZT2 than in saline controls (Fig. 2A).
Co-sinor analysis shows that for CLOCK, PER1 and c-Fos the
peak of the expression is altered to occur earlier in the lights
on phase in both MPD and ATO treated animals (e.g. to ZT2
from ZT8 for CLOCK and PER1 expression; Table 1).
There was a significant main effect of treatment on PER1
expression in the paraventricular nucleus of the hypothala-
mus (PVN; F2,70¼24.3, Po0.05; Fig. 2B). Post hoc testing
revealed a general upregulation of PVN PER1 in MPD treatedFig. 2 –Modulation of clock gene products and c-Fos in the DMH and
of PER1, PER2, CLOCK and c-Fos in the dorsomedial nucleus of t
(PVN, B) in the three treatment groups. * represents Po0.05 for
treatment group at that time-point compared to the value in th
represents the time of the daily injection.animals and a downregulation in ATO treated ones (Po0.001).
There was also a significant main effect of treatment on PVN
PER2 expression (F2,70¼161.4, Po0.001) and post-hoc testing
demonstrated a reduction in PER2 expression by MPD and
ATO (both Po0.001). CLOCK was not altered by treatment in
the PVN, but there was a significant time x treatment
interaction for c-Fos expression (F6,70¼4.1, Po0.01). Co-sinor
analysis (Table 1) indicates changes in the time of peak
expression or loss of significant 24 h fit for the ATO and
MPD treated groups for PER1, PER2, CLOCK and c-Fos
expression.2.2. Diurnal clock protein expression in the limbic
forebrain and cerebral cortex
In the hippocampus there were no significant treatment
effects or time x treatment interactions in the CA1, CA3 or
dentate gyrus (DG) for PER1, PER2 and CLOCK (Fig. 3). There
were main effects on c-Fos expression in the CA1 (F2,70¼35.4,
modified Po0.05), CA3 (F2,70¼34.3,modified Po0.05) and DG
(F2,70¼23.8, modified Po0.05). Post-hoc testing revealed that
the MPD treated group showed elevated hippocampal c-Fos
(most notably at ZT2, 24 h after the last treatment), whilst
there were no significant differences between the ATO and
the saline groups (Fig. 3).
Similar to the hippocampus, there were no significant
effects of treatment or treatment x time interactions for
PER1, PER2 or CLOCK in either the basolateral amygdala
(BLA) or the central nucleus of the amygdala (CEA; Supple-
mentary Fig. 1). There was a significant main effect of
treatment on c-Fos expression in the BLA (F2,70¼12.9,
Po0.05) and in the CEA (F2,70¼8.2, Po0.05). In both CEA andPVN by methylphenidate and atomoxetine. Expression profiles
he hypothalamus (DMH; A) and the paraventricular nucleus
pairwise comparison between the value in the appropriate
e saline control group at the same time-point. The arrow
Fig. 3 –Modulation of clock gene products and c-Fos in the hippocampus by methylphenidate and atomoxetine. A: Photomicrographs
illustrating the expression of PER1, PER2, CLOCK and c-Fos in the hippocampus. The area of CA1 sampled for analysis is
outlined by the dashed rectangle, the area of CA3 used by the oval and the dentate gyrus (DG) by the dotted rectangle. Scale
bar is 100 μm. B Expression profiles of CLOCK, PER1, PER2 and c-Fos in the CA1, CA3 and dentate gyrus (DG, D) in the three
treatment groups. * represents Po0.05 for pairwise comparison between the value in the appropriate treatment group at that
time-point compared to the value in the saline control group at the same time-point. The arrow represents the time of the
daily injection.
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Fos expression at ZT2, similar to the effect observed in the
hippocampus.
In the cortical areas examined, again there were no effects
of treatment on PER1, PER2 or CLOCK expression (Supple-
mentary Fig. 2). There were significant main effects of treat-
ment on c-Fos expression in the PLC, ILC and CC (F2,70¼18.9,
P40.05; F2,70¼19.0, Po0.05; F2,70¼17.6, Po0.001 respectively).
Post-hoc analysis revealed that MPD increased c-Fos expres-
sion in all three regions of the cerebral cortex in comparison
to the saline controls (all Po0.001).
2.3. Diurnal clock protein expression in the striatum and
ventral tegmental area
There was a main effect of treatment on PER2 expression in
the caudate putamen (CPu; F2,70¼31.5, Po0.05) and post-hoc
analysis demonstrated that both ATO and MPD significantlyincreased PER2 expression (Fig. 4A). There were no significant
effects of treatment on PER1 or CLOCK in the CPu, although
there was a significant effect of treatment on c-Fos expres-
sion (F2,70¼47.7, Po0.05) with both MPD and ATO treatment
groups showing elevation of c-Fos expression. From the Co-
sinor analysis the timing of peak expression of CLOCK in the
CPu was earlier in both the MPD and ATO groups than the
saline controls, whilst the timing of the PER2 was later in the
MPD group than the saline controls (Table 1).
There was a main effect of treatment on PER1 expression
in the ventral tegmental area (VTA; F2,70¼18.1, Po0.05), with
post-hoc analysis indicating elevation of PER1 expression in
the ATO group (Fig. 4B). There was no significant effect of
treatment on PER2 or CLOCK expression in the VTA. There
was a main effect of treatment on c-Fos in the VTA
(F2,70¼25.8, Po0.001). Post-hoc analysis showed this to be a
significant increase in c-Fos in the MPD treatment group
(Fig. 4B).
Fig. 4 – Modulation of clock gene products and c-Fos in the caudate putamen and ventral tegmental area by methylphenidate
and atomoxetine. Expression profiles of CLOCK, PER1, PER2 and c-Fos in the caudate putamen (Cpu, A),and in the ventral
tegmental area (VTA, B) of the three treatment groups. * represents Po0.05 for pairwise comparison between the value in the
appropriate treatment group at that time-point compared to the value in the saline control group at the same time-point.
The arrow represents the time of the daily injection.
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there were no significant effects of treatment on PER1, PER2
or CLOCK expression (Supplementary Fig. 3). Similar to the
hippocampus, amygdala and cortical areas, where there was
also no effects on clock gene product expression, the only
effects of treatment were observed on c-Fos expression in
both the AcbC and AcbSh (F2,70¼7.0, Po0.05 and F2,70¼11.2,
Po0.05 respectively) with MPD inducing higher levels of
expression (Supplementary Fig. 3A).3. Discussion
In this study we have shown that daily administration of
both MPD and ATO exerts effects on diurnal patterns of
expression of clock gene proteins and the immediate early
gene c-Fos throughout the mouse brain. These data comple-
ment recent data from behavioural analysis that demonstrate
that MPD and ATO cause changes in both circadian and
diurnal rhythms in rodents (Algahim et al., 2009; O’Keeffe
et al., 2012; Antle et al., 2012). The modulation of daily clock
gene profiles examined in the current study might provide a
molecular correlate of the behavioural effects previously
described. The present results, taken in the context of
previous work, further appears to strengthen the contention
that commonly used ADHD medications can impact on the
circadian system and such effects may be of importance in
both the therapeutic and the side effect profile of these
agents.3.1. Methylphenidate and atomoxetine effects in the
hypothalamus.
The effects of both MPD and ATO on PER2 expression in the
SCN suggests that they modulate the master circadian clock's
function as PER2 is a core component of the molecular
clockworks. An effect on the SCN clock gene cycle would be
in keeping with some previous reports: daily methylpheni-
date treatment leads to the development of anticipatory
locomotor rhythm in the rat (Algahim et al., 2009,2010), a
finding that is congruent with our finding that daily MPD
alters the acrophase of the PER2 SCN rhythm. Our present
findings also appear to be consistent with the findings of
Antle et al. (2012) who reported that methylphenidate treat-
ment induces phase delays under a light/dark cycle and
induces lengthening of the free-running period in mice, as
well as delaying the peak in maximal SCN electrical activity.
It is not immediately apparent from the current study why
PER1 and PER2 expression are differentially regulated by both
methylphenidate and atomoxetine in the SCN, although such
differences in regulation have been described in a number of
previous studies and may be due to regulation by different
intracellular mechanisms (Coogan et al., 2011; Bendova and
Sumova, 2006). There may also be a differential response to
MPD or ATO in cells expressing PER2 and not PER1, but
previous evidence has suggested that cells expressing PER1
also express PER2 (LeSauter et al., 2003). Effects of acute
ATO on SCN CLOCK and c-Fos expression have been reported
(O’Keeffe et al., 2012), although we did not observe
any significant changes in CLOCK expression in the current
study.
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wider circadian system, including in the entrainment of the
master pacemaker and in the regulation of light input to the
retina (McClung et al., 2005; Witkovsky, 2004). Further dopa-
minergic agents have previously been shown to regulate
clock gene expression in a number of studies (Manev and
Uz, 2006). There has been less research on the roles of
noradrenaline in circadian processes, although there is a
circadian rhythm of noradrenaline release in the SCN inde-
pendently of light input (Cagampang et al., 1994). It is there-
fore possible that since MPD is an inhibitor of both dopamine
and noradrenaline re-uptake by DAT and NET (Madras et al.,
2005), and ATO selectively inhibits NET mediated noradrena-
line removal (Bymaster et al., 2002), the subsequent increases
in synaptic dopamine and noradrenaline could impact upon
such aspects of the circadian system. Moreover, since the
SCN is the site of the master circadian pacemaker, and PER2
is a core component of the molecular mechanism that drives
circadian rhythms (Dibner et al., 2010), any alteration in its
rhythm could have knock on effects upon not only the other
core clock genes and their protein products but also the
expression of clock controlled genes and downstream phy-
siological and behavioural processes.
The regulation of clock gene protein products by MPD and
ATO was also region specific. For example, in the hypothala-
mus, differential effects were observed between the SCN, PVN
and DMH. There appears to be region, drug and protein
specificity in the effects observed, and given reciprocal connec-
tions between these regions it is not possible to ascribe order
effects to the results observed (e.g. are the effects seen in the
PVN and DMH just secondary to actions on the SCN?). Both the
DMH and PVN have been strongly implicated in circadian
function and serve as important efferent regions of the SCN
and rhythmic functions associated with these regions include
the regulation of autonomic outflow, of the hypothalamic–
pituitary–adrenal axis, of feeding behaviour and also of sleep
(Saper et al., 2005). As many of these processes are dysregulated
in ADHD (e.g. Baird et al., 2011) and are also known to be
regulated by both MPD and ATO (Boonstra et al., 2007; Sofuoglu
et al., 2009), it appears plausible that MPD and ATO action on
circadian processes in the DMH and PVN may be of conse-
quence in such physiological events.
3.2. Methylphenidate and atomoxetine effects in the limbic
forebrain and cerebral cortex
PER2, CLOCK and c-Fos were not rhythmically expressed in all
the hippocampal and amygdala regions examined of the
saline treated mice, although studies have reported some of
these proteins to be rhythmic in these regions (Wyse and
Coogan, 2010; Feillet et al., 2008; Lamont et al., 2005). The
analysis of clock protein expression at four six hourly time-
points across the cycle may not provide sufficient temporal
resolution to detect significant rhythmicity in these areas.
Another possible explanation is the effects of daily saline
injections in the control group compared to expression
patterns in treatment naive animals reported in other stu-
dies. MPD treatment resulted in the loss of diurnal variation
in PER1 expression in the CA1 and CA3 regions, an effect also
observed on per gene expression in the hippocampus of ratsundergoing withdrawal after chronic morphine treatment (Li
et al., 2009). MPD also caused an increase in neuronal
activation throughout the limbic forebrain as indicated by
an increase in c-Fos expression, whereas this effect was only
observed in DG after atomoxetine treatment. These data
indicate that areas that show neuronal responses to ADHD
medication do not necessarily then also show alterations in
clock gene product expression. Alterations of circadian pro-
cesses in both the hippocampus and amygdala have been
associated with altered cognition and emotional regulation
(Gerstner and Yin, 2010; Pantazopoulos et al., 2011), processes
that are of obvious importance in the pharmacological
management of ADHD by MPD or ATO.
In the cerebral cortical areas examined, MPD did not impact
upon circadian clock protein expression whilst ATO altered the
timing of the CLOCK expression profile. MPD treatment did
however increase c-Fos expression in all three regions of the
cerebral cortex examined, thus demonstrating again that whilst
MPD does not affect circadian functioning of the cerebral cortex
it does cause a widespread increase in neuronal activation
throughout the region. A key factor in the greater effects of ATO
upon cerebral cortex circadian clock protein expression
observed could be an increased abundance of NET compared
to DAT, which has been observed in the prefrontal cortex (Koda
et al., 2010). Furthermore, ATO has been shown to also increase
dopamine levels also in the prefrontal cortex, due to the non-
selective uptake of dopamine by NET, which is blocked by ATO
(Koda et al., 2010; Bymaster et al., 2002). The frontal cortex is
known to be involved in working memory, attention, impulse
control and other executive functions (Nestler and Carlezon,
2006) and actions of methylphenidate or atomoxetine on
circadian processes in cortical areas may be of particular
importance in addressing core symptoms of ADHD.
3.3. Methylphenidate and atomoxetine effects in the
striatum and ventral tegmental area
MPD exerted a more widespread effect upon striatal protein
expression than ATO, as might be expected given its pharma-
cological mode of action. MPD also increased c-Fos expression
in the CPu and AcbSh, which is in agreement with the previous
reports of the effects of MPD on c-fos gene expression in these
areas (Steiner et al., 2010). ATO does not increase extracellular
noradrenaline levels in the striatum (Koda et al., 2010) due to a
lack of NET as demonstrated by minimal immunoreactivity
fibres (Schroeter et al., 2000) and this could therefore underlie
the lesser effects of ATO upon striatal circadian clock protein
expression in comparison to methylphenidate. In the VTA both
MPD and ATO treatments altered PER1 expression whilst MPD
increased the degree of neuronal activation as judged by c-Fos
staining. The modulation of circadian processes in the mesos-
triatal pathway by MPD and/or ATO could exert effects on
cognitive and behavioural processes implicated in the actions of
these drugs in ADHD management.
3.4. Ongoing versus acute effects of methylphenidate and
atomoxetine on clock gene product expression.
In the current study we have utilised a daily treatment
regime of daily i.p. injections of the drugs/saline at a set time
b r a i n r e s e a r c h 1 5 1 3 ( 2 0 1 3 ) 6 1 – 7 168of day. We chose such a treatment regime as it allowed us to
control the time of drug treatment, something which is not
possible with other routes (e.g. via drinking water, in which
case the drug will be delivered according to the normal
drinking rhythm as in the study of Antle et al., 2012). Such
a treatment regime raises the possibility that effects observed
at the various time points are not due to the ongoing nature
of the treatment, and rather are elicited acutely in response
to the last treatment. Given that both atomoxetine and
methylphenidate have relatively short half-lives in humans
and rodents (24 h; Coghill and Seth, 2006; Cui et al., 2007; Thai
et al., 1999; Mattiuz et al., 2003), it is interesting to note that
for methylphenidate treated animals, a number of brain
areas examined show elevation of c-Fos at ZT26, a full 24 h
following the final treatment, suggesting that at least in part
the effects of the treatment regimes observed in this study is
due to the ongoing nature of the treatment. In these types of
experiments there is the complicating interaction between
the time course of drug induced effects, the ambient photic
environment and the underlying chronobiological rhythms of
the factors being examined. Future studies may investigate
the effects of single treatments of atomoxetine and methyl-
phenidate on 24 h profiles of clock genes in the brain.
A separate issue is the timing of the doses at ZT2 in our
study. Previous studies examining methylphenidate modula-
tion of diurnal rhythms have dosed at a similar time point
(ZT1; Algahim et al., 2009, 2010), whilst the study of O’Keeffe
et al. (2012) who examined effects of acute atomoxetine
treatment on circadian parameters found that treatment
during the subjective day elicited phase shifts, whilst those
during the active night phase did not. Changes in clock gene
product expression levels at any given time point may be due
to an acute up/downregulation, or via a phase shift of the
underlying rhythmic expression and possibly to drug-related
behavioural activation/depression which in turn might alter
the photic exposure of the animal (e.g. by the animal showing
greater activity in the light on phase, during which it would
normally be behaviourally quiescent). Equally any beha-
vioural activation induced by drug treatment may act itself
as a non-photic type zeitgeber to feedback on the clock and
alter rhythmicity. Interestingly, Schaap and Meijer (2001)
demonstrated that light and behavioural activity have oppos-
ing actions on SCN neuronal function. It may be the case,
especially for methylphenidate, that drug application induces
behavioural activation in the lights on phase (which would be
expected to inhibit SCN neuronal excitability) but that such
an activation may also increase light perception (in a phase
when animals would normally often be asleep with closed
eyes), which would have the effect of increasing SCN neuro-
nal activity. Therefore the effects of any behavioural activa-
tion and increased light exposure may cancel each other out,
in which case the changes in SCN PER2 expression observed
might be explained by a direct action of the drug on clock
mechanisms, rather than being mediated indirectly through
changes in behavioural state and light perception. Further
experiments that evaluate such behavioural effects in paral-
lel with changes in clock gene product expression would be
very useful in addressing such an issue.
Whether the timing of treatment used in our present
study recapitulates the clinical usage of these drugs isdifficult to interpret in terms of the use of a nocturnal rodent
in our study, and the lack of clarity on the mechanism that
determine day/night activity. For example, the SCN rhythms
of both diurnal and nocturnal species are very similar
(Ramanathan et al., 2010). Typically patients taking either
methylphenidate or atomoxetine will take a number of doses
a day (due to their relatively short half lives), or be treated
with slow release formulations of methylphenidate starting
in the morning, and so it is likely that patients are exposed to
these drugs through the lights on phase, during which the
SCN appears to be in a similar phase in diurnal and nocturnal
species. Further work examining the phase-dependency of
methylphenidate's and atomoxetine's effects on circadian
processes would clarify such questions.3.5. Conclusions
We have demonstrated widespread effects of both MPD and
ATO on the expression of circadian clock gene products in the
mouse brain in a neuroanatomically differentiated manner.
The pharmacological modulation of the circadian clockwork
observed could have implications for the regulation of var-
ious behaviours that are governed by these brain regions, and
could help explain the wide variety of therapeutic and
adverse side effects of these drugs. Having said this, it is
important to note that the functional consequence of clock
gene expression in extra-SCN sites remains largely unknown,
and as such future studies investigating behavioural conse-
quences of long-term MPD and ATO treatment on circadian
parameters would be illuminating in light of the molecular
data presented here. Further, assessment of the impact of
these drugs upon the circadian rhythms in animal models of
ADHD and in both healthy control and patient populations
would contribute to our understanding of the therapeutic
mechanisms of these drugs and may lead to a more effica-
cious therapeutic deployment of these drugs in the clinic
(e.g. by examining effects of time of dosing on ADHD
symptom relief).4. Experimental procedures
4.1. Animals
Male C57BL/6J mice (n¼75, 8 weeks, Charles River, St Germain
sur L’Arbresle, France) were housed in cages of three, with ad
libitum access to food and water, and constant temperature
and humidity, and were habituated to the housing conditions
prior to beginning the experiments. Male mice were used, as
is common in chronobiology, to avoid any possible interac-
tions between oestrous stage and drug effect. As such, effects
reported in this study may not extrapolate to females.
The mice were subject to a 12:12 light/dark cycle, with lights
on at 6 am (designated Zeitgeber Time (ZT) 0), using standard
fluorescent light bulbs (100 lx at cage level). These experi-
ments adhered to the guidelines outlined in the Animals
(Scientific Procedures) Act, 1986, the European Communities
Council Directive 86/609 and by the Research Ethics Commit-
tee, School of Medicine, Swansea University. All efforts were
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experienced.
4.2. Drug treatments
The mice underwent daily treatment with either 2.5 mg/kg MPD
(Methylphenidate hydrochloride, Sigma-Aldrich, UK), 2.0 mg/kg
ATO (Tomoxetine hydrochloride, Tocris Bioscience, UK) or a
0.9% saline control. The injections were given in a volume of
5 ml/kg, in 0.9% saline and administered intraperitoneally, once
a day at ZT2 for 7 days. The doses of both ATO and MPD are
based on numerous previous studies showing efficacy of action
at these concentrations and the relevance of these doses to
those used in clinical settings (e.g. Bymaster et al., 2002;
Algahim et al., 2009; O’Keeffe et al., 2012; Keck et al., 2012).
4.3. Tissue collection
On day 7 of treatment, 6 mice were killed from each treat-
ment group at each of the 4 sampling time-points: ZT8, ZT14,
ZT20 and ZT26. The ZT26 sampling was the last time point,
occurring 24 h after the final treatment and 2 h after lights of
the light/dark cycle. This procedure was carried out in a light-
proof room and under red light for those mice sampled in the
dark phase of the cycle. Mice were anaesthetised with chloral
hydrate, prior to transcardial perfusion with 4% paraformal-
dehyde (PFA). Brains were removed and post-fixed in 4% PFA
at 4 1C overnight, and stored in 0.1 M phosphate buffer (PBS,
pH 7.4) at 4 1C. The brains were then cryoprotected in 30%
sucrose at 4 1C and sliced into 30 μm sections using a
freezing-stage sliding microtome (Leica, Germany).
4.4. Immunohistochemistry
Free-floating sections were processed for c-Fos, PER2, PER1 and
CLOCK immunohistochemistry using a standard avidin-biotin
complex (ABC)/nickel-DAB protocol (e.g. Beynon et al., 2009).
Primary antibodies used were c-Fos (sc-52; dilution 1:8000; rabbit
polyclonal; Santa Cruz Biotechnology, UK), PER2 (PER21-A; dilu-
tion 1:1000; rabbit polyclonal; Alpha Diagnostic International,
USA), PER1 (sc-7724; dilution 1:500; goat polyclonal; Santa Cruz
Biotechnology, UK) and CLOCK (sc-6928; dilution 1:500; goat
polyclonal; Santa Cruz Biotechnology, UK). All sections under-
went these same standard conditions, in order to minimise
inter-assay variability and where feasible tissue sections, across
time and treatment groups, for the same antigen in any given
anatomical region were run in parallel. Antibody specificity was
confirmed by processing sections using the standard immuno-
histochemistry protocols described above, but with immunising
peptide incubation, which blocked immunostaining in each case.
The use of these antibodies has been previously described (Wyse
and Coogan, 2010; Coogan et al., 2011).
4.5. Image analysis
A Zeiss Axioskop light microscope (Zeiss, Jena, Germany)
with an Axiocam digital camera was used to examine the
brain sections. Three to six images were quantitated per
time-point, region and mouse. The cell/count per area was
calculated using image analysis software (ImageJ 1.43υ,National Institutes of Health, USA). As area was not calibrated
in our image analysis we express the cell counts as arbitrary
units. The images were adjusted for background, and a
threshold value was set that was optimal for the visualisation
of each antigen. This threshold was then applied to all brain
areas examined for that antigen and cells expressing immu-
nostain in excess of the threshold were counted as being
immunopositive. There are important caveats to such analy-
sis, such as once a cell express immunolabel above a certain
threshold it is counted, irrespective of stain intensity, and
there is no necessarily a linear relationship between antigen
concentration and subsequent immunostaining (Rieux et al.,
2002). However, such immunohistochemical approaches are
widely used in chronobiology and are a mainstay for asses-
sing clock gene protein product expression (e.g. Amir et al.,
(2004); Debruyne et al., (2006); Challet et al., 2012).
Anatomical regions were identified according to the stereo-
taxic coordinates defined in the mouse brain atlas (Paxinos and
Franklin, 2004). Immunoreactivity was examined in the supra-
chiasmatic nuclei (SCN) at the mid-rostral level, the paraven-
tricular nucleus of the hypothalamus (PVN), the dorsal medial
nucleus of the hypothalamus (DMH), the basolateral (BLA) and
central (CeA) amygdala, the hippocampus (CA1, CA3, dentate
gyrus (DG)), the caudate putamen (CPu), the ventral tegmental
area (VTA), the nucleus accumbens including the core (AcbC)
and shell (AcbSh) regions, and the cerebral cortex including the
prefrontal infralimbic cortex (ILC), the prefrontal prelimbic
cortex (PLC) and the cingulate cortex (CC). The areas of interest
within these structure analysed are shown in Figs. 1 and 3 and
supplementary Fig. 4. These regions were chosen based on their
roles in the circadian system (e.g. SCN, and its major efferent
regions PVN and DMH, semi-autonomous oscillators in the
hippocampus, amygdala (Guilding and Piggins, 2007), and/or
implication in ADHD and ADHD drug action (e.g. dopaminergic
system, VTA, CPu, AcbSh and AcbC, prefrontal cortex impli-
cated in executive dysfunction in ADHD (Coogan et al., 2012).4.6. Statistical analysis
Average immunoreactivity was calculated per mouse, time-
point, treatment group and brain region. SPSS (IBM Corpora-
tion, USA) was used to run 2-way analysis of variance
(ANOVA), with zeitgeber time and treatment (Saline, MPD or
ATO) as the factors, with Tukey post-hoc testing to describe
specific pairwise effects within main effects. To correct for
multiple hypothesis testing, results from 2-way ANOVAs
were corrected in a stepwise manner with the Holm-
Bonferroni method, and the P values cited in the results is
the P value after such correction was applied. Twenty four
hour Cosinor analysis was performed using statistical soft-
ware (CircWave v1.4, Department of Chronobiology, Univer-
sity of Groningen, Netherlands), to test whether the data
exhibited a significant diurnal rhythm. This programme
determines if a statistically significant (Po0.05) sinusoidal
wave can be fitted to the data, by automatically adding
harmonics to the wave fit to best describe the data.
The following function describes the wave-form:
f ðtÞ ¼ aþ ∑
∞
i ¼ 1
pi sin i2π
t
τ
þ qi cos i2π
t
τ
 
b r a i n r e s e a r c h 1 5 1 3 ( 2 0 1 3 ) 6 1 – 7 170where a is the average; i is either 1, 2, 3, when 1 it indicates
the fundamental wave, when 2 it describes the first harmo-
nic, when 3 it describes the second harmonic. pi is the sine
coefficient of the (i−1)th harmonic, qi is the coefficient of the (i
−1)th harmonic; t is the time-point value (modulo τ); f(t) is the
calculated function value at time point t, a and b are linear
estimates for the sine and cosine contribution to a flat line
(when i¼0), the fundamental wave (i¼1), first harmonic (i¼2),
second harmonic (i¼3). For our analysis, optimal fits were
obtained with the fundamental wave.Acknowledgments
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